Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
GSK responds to UK Industrial Strategy
Read our response to the UK Industrial Strategy White Paper.
Read more -
ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced the start of a phase III study with a ...
Read more -
GSK submits landmark IMPACT data to US regulatory authority to support expanded label for Trelegy Ellipta
GSK submits landmark IMPACT data to US regulatory authority to support expanded label for Trelegy Ellipta
Read more -
Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food an...
Read more -
Trelegy Ellipta once-daily single inhaler triple therapy gains marketing authorisation in Europe for the treatment of COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta
Read more -
GSK receives European marketing authorisation for self-injectable formulation of Benlysta for the treatment of systemic lupus erythematosus
The approval is for a single-dose prefilled syringe and a single-dose prefilled pen (autoinjector) presentation, administered as a once weekly injection of 200mg.
Read more -
First long-term efficacy analysis on the effect of GSK’s Benlysta on rate of organ damage progression in SLE versus standard therapy alone
GSK today announced results of the first study assessing levels of organ damage in patients with active systemic lupus erythematosus (SLE) treated with Benlysta (belimumab) plus...
Read more -
Patrick Vallance, President, R&D, GSK to become UK Government's Chief Scientific Adviser
Patrick Vallance, President, R&D, GSK to become UK Government’s Chief Scientific Adviser
Read more -
Dr Hal Barron appointed Chief Scientific Officer and President, Research & Development, GSK
Dr Hal Barron appointed Chief Scientific Officer and President, Research & Development, GSK
Read more -
GSK submits US regulatory application for mepolizumab in eosinophilic chronic obstructive pulmonary disease (COPD)
GlaxoSmithKline plc today announced the submission of a supplemental Biologics License Application (sBLA) to the United States Food and Drug Administration (FDA
Read more -
New multi-country survey reveals need for improved awareness around long-term impact and appropriate use of corticosteroids in SLE management
Results from EnABLE highlight an opportunity for increased awareness on appropriate corticosteroid use and a more proactive approach to the management of SLE.
Read more -
GSK’s investigational BCMA antibody-drug conjugate receives Breakthrough Therapy Designation from US FDA for relapsed and refractory multiple myeloma
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for GSK2857916 monothe...
Read more -
GSK study demonstrates superiority of Anoro Ellipta to Stiolto Respimat in improving lung function in chronic obstructive pulmonary disease
GlaxoSmithKline plc and Innoviva, Inc. today announced positive data from a study comparing a once-daily long-acting muscarinic antagonist (LAMA) and a long-acting beta agonist
Read more -
ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV
ViiV Healthcare, today announced results from the phase III BRIGHTE study of fostemsavir in heavily treatment-experienced (HTE) patients with HIV-1 infection.
Read more -
Public-private consortium aims to cut preclinical cancer drug discovery from six years to just one
Lawrence Livermore National Laboratory, Frederick National Laboratory for Cancer Research, GSK, and University of California San Francisco will combine vast data stores, superco...
Read more -
GSK delivers Q3 sales of £7.8 billion, +4% AER, +2% CER
Total EPS 24.8p, +49% AER, +46% CER; Adjusted EPS 32.5p, +3% AER, flat CER
Read more -
CDC’s Advisory Committee on Immunization Practices recommends Shingrix as the preferred vaccine for the prevention of shingles for adults aged 50 and up
Committee recommends immunization for up to 62 million additional adults in the US
Read more -
Shingrix approved in the US for prevention of shingles in adults aged 50 and over
Pooled clinical trial results showed > 90 percent efficacy across all age groups
Read more -
GSK receives World Health Organization Prequalification for Synflorix pneumococcal vaccine four-dose vial
The World Health Organization (WHO) has awarded prequalification for the new four-dose vial presentation of Synflorix pneumococcal vaccine targeted mainly for countries that rec...
Read more -
GSK announces first approval of Shingrix in Canada
The only shingles vaccine to achieve ≥90% efficacy in adults aged 50 and over
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
